Background: Hepatitis B virus (HBV) infection increases the risk of liver disease and hepatocellular carcinoma. Small interfering RNA (siRNA) can be a potential new tool for HBV therapy. Given the high heterogeneity of HBV strains and the sensitivity towards sequences changes of siRNA, finding a potent siRNA inhibitor against the conservative site on the HBV genome is essential to ensure a therapeutic application.
Background
Worldwide, there are over 350 million people persistently infected with hepatitis B virus (HBV) [1] . Chronic HBV infections may have serious consequences, including acute hepatitis, as well as chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) [2] . Together, these are responsible for over 1 million deaths worldwide each year [3] . Current treatments for HBV infections are not only expensive and have significant side effects, but also only induce a partial response [4] [5] [6] .
In eukaryotic cells, RNA interference (RNAi), a type of double-stranded (ds) RNA, initiates and directs sequence-specific, post-transcriptional silencing of homologous genes [7, 8] . It has been demonstrated in previous studies that expression and replication of HBV can be suppressed by siRNA or shRNA with clinical implications [9] [10] [11] . However, the wide heterogeneity of HBV sequences may render RNAi inhibitors ineffective.
To explore this further, 40 shRNA expression plasmids were constructed to target the sites that were conserved among HBV genotypes A through I. Their anti-HBV efficacy was then evaluated in vitro and in vivo.
Results

Screening for effective and broad anti-HBV shRNA
The shRNA plasmids co-transfected with two HBV 1.35 plasmids (N10 and Y1021) exhibited varying levels of extracellular HBsAg expression (Table 1 ). Of the forty shRNA plasmids, four plasmids (B245, B376, B1581 and B1789, Figure 1 ) were selected as candidates for further research based on their remarkable inhibitory ability and also relatively lower off-target probability (off-target score of above 30). The sequence conservation among the A to I genotypes for B245, B376, B1581 and B1789 were 95.1% (95%CI: 92.2~97.2), 88.7% (95%CI: 84.7~91.9), 97.3% (95%CI: 94.8~98.7), and 97.6% (95% CI: 95.2~98.9), respectively ( Table 2 ). The data also shows that the target sequences of B245, B1581 and B1789 were more conserved than the target sequence of B376 (p < 0.05) in genotype B and C ( Table 2) . 
Adverse side-effects evaluation for selected shRNA plasmids
The B245, B376, B1581, and B1789 plasmids were transfected into Huh7 cells to determine cytotoxicity by the WST-8 assay. No significant siRNA-induced cytotoxicity was observed for these siRNA when compared to an empty pSUPER vector (p = 0.66, data not shown). The mRNA levels of four major interferon stimulated genes (STAT1, OAS1, GBP1 and MX1) in transfected cells were measured by quantitative realtime PCR with GAPDH mRNA acting as a control. As shown in Figure  2 , between values 1 and 2, logarithmic increases for the IFN-stimulatable mRNAs were only observed in the IFN-treated cells, but not observed in any of the shRNA treated cells vs. untreated cells. From this, it can be concluded that an IFN response is not activated by these anti-HBV siRNAs.
ShRNA inhibit gene expression of HBV strains with different genotypes in vitro
The levels of cytoplasmic HBV pg/pc RNA (3.5 kb) and HBV DNA in cultured supernatants were determined by realtime RT-PCR/PCR and presented in Figure 3 . The pg/pc RNA level of five HBV strains with different genotypes were reduced by 58%~93% in B245(69%~93%), B376(59%~91%), B1581(67%~90%) and B1789(58%~88%) treatments, while the HBV DNA level observed in supernatants was decreased by 77%~99% in these shRNA plasmid treatments (B245: 83%~99%, B376: 79%~99%, B1581:88%~98%, B1789: 77%~99%). In addition, the extracellular and intracellular antigen levels in Huh7 cells that were co-transfected with HBV and shRNA plasmids were also determined ( Figure 4 ). In the shRNA-treated Huh7 cells, the average extracellular HBsAg expression level of all five HBV strains decreased by 1 0.36 logs. The average intracellular HBsAg expression level decreased by 1.47 ± 0.33 logs, while the extracellular HBeAg levels decreased by 1.04 ± 0.23 logs, and the intracellular HBcAg levels by 1.71 ± 0.49 logs. The effect of the siRNA treatment on HBeAg levels was weaker than that on the HBsAg or HBcAg levels (P < 0.001, Figure 5 ).
Inhibition of gene expression of HBV strains with different genotypes in vivo
Using the mouse model of acute hepatitis B virus infection [12] , the profiles of serum HBsAg and HBeAg were used to evaluate the effect of shRNA over nine days ( Figure 6 ). All HBV plasmids expressed detectable HBsAg and HBeAg in mice sera ( Figure 6 ). As compared to the control mice (HBV+L1254), B245 and B376 treatments reduced HBsAg expression by over 99% in all five HBV genotypes. Furthermore, B1581 and B1789 treatments suppressed HBsAg by over 99% in mice infected with HBV genotypes A, B, C and D. In a novel W29 strain representing genotype I however, B1581 and B1789 treatments only reduced HBsAg expression by about 90%. With regards to serum HBeAg for genotypes A, B, C, D and I, B245, B376, B1581 and B1789 treatments suppressed HBeAg by 96%~99%, 79%~99%, 94%~99%, and 89%~99%, respectively. The overview of the results shows that B245 is the most potent agent.
Discussion
Activated RNAi pathway can silence HBV replication and expression [13, 14] . However, in most previous studies, the activity of RNAi against HBV is often evaluated with only one HBV strain [15] [16] [17] [18] . Nine HBV genotypes (including a newly identified genotype "I"), designated as the letters A through I, have been recognized with an accompanying sequence divergence of >8% over the entire genome [19] [20] [21] . The influence of genotypes on HBV replication efficacy and antigen expression level had been proved to be various and that may further associate with clinical outcomes and antiviral treatments responses [22] . Hence, RNAi designed for one genotype may not necessarily be effective against another genotype. Given the high heterogeneity of HBV strains and the sensitivity of siRNA to the sequence changes, designing siRNA targets against the conservative site on HBV genome is essential to ensure activity across all genotypes [23] . Relative gene expression level Figure 2 The expression profile of four major interferon stimulated genes (ISGs) in shRNA plasmids transfected cells. Cytoplasmic RNAs, from Huh7 cells treated with or without IFNα-2a or transfected with either pSUPER vector or shRNA plasmids, were analysed by realtime RT-PCR for IFN stimulated genes STAT1, OAS1, GBP1 and MX1. The values on the figure, plotted as "Relative gene expression level" on the y-axis, were calculated as the mRNA levels of ISGs divided by the GAPDH (control) mRNA level. Student t test was used to assess the difference between shRNA plasmids (including empty pSUPER vector) of transfected cells and nontransfected cells (mock). No significant difference was observed. In shRNA expression systems, two different promoters are predominantly used: U6 and H1, both driven by human polymerase III (poly III). Compared to Pol II promoters, Pol III promoters generally possess a greater capacity to synthesize RNA transcripts of a higher yield and rarely induce interferon responses [17, 24] . However, a previous study noted that U6 Pol III-expressed shRNAs may cause serious toxicity in vivo by saturating the endogenous miR pathway [25] . In this report, we constructed 40 shRNA plasmids (Table 1) with various targets, using a human H1 Pol III promoter. The target sequences of the final four selected shRNA plasmids demonstrated high sequence conservation among A to I genotypes and significant inhibition activity, in both Huh7 cells and mice, against the expressions of HBV RNA, DNA and antigens in genotypes A, B, C, D and I. The inhibitory efficacy of these shRNAs (B245, B376, B1581 and B1789) however, varies significantly against the various genotypes for different viral markers in different models (Figure 3, 4 , 5 and 6). Such differences in efficiency may be due to differences in the mRNA's secondary structure or the target site accessibility [26] . B245 was the most effective of the four candidates.
It should be noted that both the cell-transfection model and hydrodynamic injection model more closely resemble an acute model of a HBV infection. This is a potential limitation in this study, as most individuals who need anti-HBV therapy are chronically infected. Compared to the HBV transgenic mouse models and stably transfected cell lines, the former are more flexible and convenient in evaluating the efficacy of shRNAs as a way to inhibit various HBV strains. Nevertheless, the effective shRNA candidates should be studied further in different models. Because HBV contains overlapping open reading frames (ORFs) and all four HBV transcripts overlap in their 3′ terminals, a single siRNA targeting multiple areas could be designed to maximize inhibitory potency [23] . The siRNAs targeting C ORF, such as B2389~B2397, presented in Table 1 , show activity only against the 3.5 kb pregenomic RNA, but are unlikely to show any activity against the other three transcripts (Figure 1) . Meanwhile, all four siRNAs demonstrated more silencing activity with regards to HBsAg expression than HBeAg expression for various genotypes in the cell cultures and mice. The targets on both however were the same in the HBV transcripts for the two proteins (Figure 4 and Figure 5 ), which was also observed in a previous study [23] . HBcAg, a viral capsid correlated with viral replication [27, 28] , was silenced as effectively as HBsAg, but HBeAg was not (Figure 4) .
The registered agents currently available for the treatment of HBV infections, such as interferon and nucleoside analogues, can dramatically decrease HBV DNA levels and induce particular HBeAg loss, but will rarely cause HBsAg loss in chronic hepatitis B patients [29] [30] [31] [32] . RNA interference, on the other hand, can theoretically be directed to cleave any target RNA, providing a novel methodology for anti-HBV therapy [33] . In the present study, and supported by other studies [13, 34, 35] , using RNAi as an inhibitor for HBV effectively reduces viral antigen levels, including HBsAg. It can be speculated that RNAi-treatments may offer complementary effects for current anti-HBV therapy. However, the final application of RNAi-based anti-HBV drugs depends on the development of effective and safe RNAi delivery systems.
Conclusions
In summary, four candidate shRNA plasmids significantly inhibited HBV genotypes A, B, C, D and I in vitro and in vivo. A potential avenue of investigation would be a combination strategy of various siRNA in a single transcript to improve efficacy and also prevent or at least delay the rise of viral escape mutants.
Methods
HBV Plasmids
Five HBV 1.35-fold genome plasmids -N10 (genotype Ae, AY707087), C4371 (genotype Ba, GU357842), Y1021 (genotype C1, GU357845), Y10 (genotype D1, GU357846) and W29 (genotype I1, GU357844) were used for transfection and hydrodynamic injection. The constructions and molecular and phenotypic characteristics are described in our previous report [36] .
Bioinformatics Analysis
To define the conservative sites on HBV genomes amongst the various genotypes, all available complete genome sequences of HBV, as of April 2009, were downloaded from GenBank. Multiple alignment was done with ClustalX2 under default settings (Gap Opening:10, Gap Extension: 0.2, Delay Divergent Sequences (%): 30, DNA Transition Weight: 0.5, Use Negative Matrix: Off). The most representative and informative sequence in terms of phylogeny were collected as a dataset and the most similar sequences were removed using all pairwise distance scan. A total of 327 HBV genomes including A-I genotypes and nearly all reported subtypes were remained in the final dataset. The genotypes and subtypes of six HBV genomes isolated in the study were submitted to phylogenetic analysis using MEGA 4.0 software (data not shown). Forty sites with conservative sequences were selected and the shRNA plasmids were constructed ( Table 1 ). The designed siRNA were evaluated for potential off-target effects by the online SOS program http://rnai.cs.unm.edu/offTarget. The sequences and positions of the forty designed shRNA targets are shown in Table 1 .
ShRNA Plasmids
ShRNA plasmids were cloned downstream of the human H1 promoter in the vector pSUPER [37] . The target sites for siRNA were chosen based on conservative sites among the major HBV genotypes and subtypes. An shRNA plasmid targeting the firefly luciferase gene was used as a control (L1254: TGG CTA CAT TCT GGA GAC ATA).
Cell Culture and In Vitro Transfection
The plasmids used for in vitro transfection were purified with PlasmidSelect Xtra Starter Kit (GE Health, Sweden) and the concentrations were determined by the UVspectrophotometric method. To determine the ability of siRNA to inhibit HBV gene expression in cell cultures, Huh7 cells were co-transfected with 4 μg of HBV plasmids, 1 μg of shRNA plasmids and 0.4 μg of a pcDNA3.1-SEAP plasmid using Lipofectamine 2000 (Invitrogen, Shanghai, China) following the manufacturer's instructions. They were then harvested four days later. The pcDNA3.1-SEAP plasmid is a reporter plasmid expressing secreted alkaline phosphatase and used for transfection efficiency standardization by estimating SEAP enzymatic activity (Pierce; Kunming, China) in the culture supernatant.
Evaluation for Potential Adverse Effects of siRNA
Possible adverse effects of shRNA on cells were evaluated using morphology criterion, growth rate assessment, and by noting the cytotoxicity profile of transfected cells. Cytotoxicity was determined through a WST-8 assay (Cell Counting Kit-8, Beyotime, Shanghai, China) [38, 39] . The number of viable cells was then determined by absorbance measured at 450 nm on an automated plate reader. The potential off-target effects of siRNA were evaluated by monitoring the IFN response. Huh7 cells were transfected with 1 μg of shRNA plasmids. Non-transfected cells treated or untreated with 500 IU of IFNα-2a (Anfulong, Huadali Company, China) for 24 h served as a positive control [40] . Expression profile of four major interferon-stimulated (STAT1, OAS1, GBP1 and MX1) were analyzed by a quantitative RT-realtime PCR using the previously reported primers while the GAPDH level served as a control [41] .
Mice Experiments
To evaluate the anti-viral effects of siRNA in vivo, an HBV hydrodynamic injection was conducted in BALB/c mice. Briefly, 50 μg of purified HBV plasmid and 10 μg shRNA plasmids were diluted to 2 mL with physiological saline and then injected into the tail vein within 5-10 s. Mice sera were assayed every day for HBsAg and HBeAg from Day 0 to Day 9. For each group, five mice aging from 4-6 weeks were used [42] . All animals received humane care and the study protocol complied with the institution's ethics guidelines.
Measurement of HBV RNA and DNA
For detection of the cytoplasmic HBV RNA, total RNA was extracted from cells using Tripure Isolation Reagent (Roche Applied Science, Switzerland) according to the manufacturer's instructions. Potential residual DNA contamination of RNA preparations were excluded by DNase I digestion. Ten nanograms of RNA were analysed by AccessQuick realtime RT-PCR System (Promega, USA) on a CFX96 instrument (Bio-Rad, USA). The HBV pg/pc (pregenomic/preCore) RNA level was detected by primers PGP (-CACCTCTGCCTAAT-CATC, nt1826-nt1843) and BC1 (GGAAAGAAGTCA-GAAGGCAA, nt1974-nt1955) [43] using probe CP2 (HEX-ATGTTCATGTCCTACTGTTCAAGCC-BHQ2). The transcript copy number was normalized to those of GAPDH.
For the HBV DNA assay, 100 μL of supernatant was pre-heated at 50°C for 20 minutes and then treated with 1 U DNase I for 2 hours to eliminate residual plasmids. The reaction was terminated by EDTA at a final concentration of 10 mM. The mixture was then incubated at 70°C for 10 min and the HBV DNA was extracted using QIAamp DNA blood kits (QIAGEN, Hilden, Germany). HBV DNA quantification assays were performed using a commercial real-time PCR kit (Kehua, Shanghai, China).
Determination of HBV Antigens
HBsAg, HBeAg and HBcAg levels were determined by chemiluminescence using commercial assay kits (Wantai, Beijing, China). The relative level of each antigen was expressed as an S/CO (signal/cutoff) value, on a linear range from 1 to 1000 for all three assays. The lower detection limit was 10 pg/mL for the HBsAg and HBeAg assays, and 50 pg/ml for the HBcAg assay. In regards to the intracelluar HBV antigen assay, the transfected cells were treated with a suitable lysis buffer (20 mM HEPES, 1 mM EGTA, 100 mM NaCl, 5 mM Mg 2 Cl, 0.4% n-Dodecyl β-Dmaltoside, n-Dodecyl β-D-maltoside, and 10% Glycerol) at room temperature for 30 minutes and the supernatants were separated through centrifugation and used for immunoassay.
Statistical Evaluation
Statistical analyses were performed using independent Student t test or Mann-Whitney U test (GraphPad Software, San Diego California USA,). Differences were considered to be statistically significant for p values ≤ 0.05. 
